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Background: The purpose of this study is to investigate whether 18 F-fluorodeoxyglucose (FDG) micro-positron
emission tomography-computed tomography (microPET-CT) can be used to monitor a metabolic response to
gefitinib in nude mouse tumor xenografts.
Methods: Sixteen nude mice were implanted with human A431 epidermoid carcinoma cells and ten with human
A549 lung adenocarcinoma cells, and the tumors were allowed to grow to an approximate size of 150 mm3. Ten
and five of these mice, respectively, received intragastric gefitinib (100 mg/kg) once daily for 14 days, whereas six
and five, respectively, received sterile water. Tumor metabolic activity was assessed by 18 F-FDG microPET imaging
before treatment (day 0) and on days 2, 7, and 14. Tumor uptake of 18 F-FDG was determined from a region-of-interest
drawn around the tumor, and the maximum percentage injected dose per gram (%ID/gmax) was calculated. Tumor
volume measured on day 14 by microCT was used to categorize tumors as sensitive, stable, or resistant to gefitinib,
and pathologic changes in these tumors were analyzed.
Results: On day 2, the average changes in 18 F-FDG uptake by A431 tumors sensitive, stable, and resistant to gefitinib
were −30.92% ± 6.66%, −5.68% ± 6.95%, and 7.72% ± 3.85%, respectively (P < 0.05 each), with no significant differences
in the sizes of tumors sensitive and stable to gefitinib (P = 0.169). On day 7, sensitive tumors were significantly smaller
than stable tumors (P = 0.034). On day 14, areas of necrosis were observed in gefitinib-sensitive tumors, with tumor
necrosis ratios differing significantly among the sensitive, stable, and control groups (P < 0.05 each). In mice implanted
with A549 cells, however, tumor 18 F-FDG uptake, volume, and percent necrosis did not differ significantly between
gefitinib-treated and untreated mice on days 0, 2, 7, and 14 (P > 0.05 each).
Conclusions: F-FDG uptake is a sensitive method of detecting metabolic changes in tumors associated with therapy
in vivo.
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Epithelial growth factor receptor tyrosine kinase inhibi-
tors (EGFR-TKIs) have significant antitumor activities,
with clinical benefits observed in patients with various
tumor types [1-4]. Unfortunately, however, responses
have been seen only in subgroups of patients [3,5], mak-
ing it critical to select only those patients who could
benefit from treatment with EGFR-TKIs.
Specific mutations in the K-RAS and EGFR genes
(exons 18, 19, and 21) in tumors have been shown to
be biomarkers of response to EGFR-TKI [6,7]. Although
these genetic markers may be used to predict treatment
outcome, these tests are invasive, unpleasant, and incon-
venient for patients. During the course of treatment, it is
difficult to repeatedly acquire appropriate tumor samples
for monitoring responses to EGFR-TKI [8]. There is a
clear clinical need for noninvasive, safe, real-time, quan-
titative, and readily available approaches to monitor
therapeutic responses to treatment, thus improving pa-
tient management.
Positron emission tomography (PET) imaging, which
shows the early effects of treatment on tumor metabolism,
has been widely used in the clinical management of patients
with cancer. 18 F-fluorodeoxyglucose (FDG) PET-computed
tomography (PET-CT) has been used to measure metabolic
responses of tumor to treatment, including chemotherapy,
radiotherapy, and targeted therapy [9,10]. Indeed, clinical
trials have shown that 18 F-FDG PET-CT imaging may be a
reliable surrogate marker of early therapeutic responses and
clinical benefits [11].
Treatment of non-small cell lung cancer (NSCLC) cell
lines sensitive to the EGFR-TKI gefitinib with this agent
resulted in a decline in 18 F-FDG uptake within 2 h,
before the inhibition of cellular proliferation and the
induction of apoptosis [12]. In addition, 18 F-FDG uptake
by gefitinib-sensitive xenografts in mice began to decline
as soon as 48 h after initial treatment with gefitinib. A re-
cent evaluation in 20 patients with lung adenocarcinoma
treated with gefitinib suggested that changes in tumor 18
F-FDG uptake may predict response and outcome [13].
Patients who later exhibited longer progression-free sur-
vival (PFS) showed a 20% standardized uptake value
(SUV) decrease in 18 F-FDG uptake after 2 days of gefi-
tinib therapy. A more recent study, assessing 18 F-FDG
PET-CT in 23 patients with NSCLC who received neoad-
juvant EGFR-TKI, found that metabolic response after
7 days could predict pathological response [14]. These re-
sults indicate a need for additional prospective studies to
confirm whether change in tumor 18 F-FDG uptake after
2 days of treatment with an EGFR-TKI is an early sensitive
marker of its effectiveness.
To investigate whether 18 F-FDG PET-CT can predict
pathological responses after 2 days of gefitinib treatment
and to determine the optimal cutoff value of 18 F-FDGuptake for detecting sensitivity to treatment, we assessed
the relationship between gefitinib treatment and 18 F-FDG
uptake, as well as between changes in 18 F-FDG uptake
and tumor pathology in human tumor-bearing mice.
Methods
Animals
All animal experiments were approved by the PUMA
Institutional Animal Research Committee. This study
used 26 female Balb/c nude mice 6 to 8 weeks old and
weighing 20 to 24 g.
Xenograft models
The human A431 epidermoid carcinoma and A549 lung
adenocarcinoma cell lines were generously provided by the
Institute of Laboratory Animal Science, Chinese Academy
of Medical Sciences & Comparative Medical Center, Peking
Union Medical College. A431 cells, in which the wild-type
EGFR gene is amplified and large amounts of the protein
expressed, are sensitive to EGFR-TKIs [12]. In contrast,
A549 cells, which express wild-type EGFR, have a Ras mu-
tation responsible for resistance to EGFR-TKIs.
All cells were grown in DMEM containing 10%
fetal calf serum, 100 IU/mL penicillin, and 100 μg/mL
streptomycin at 37°C in an atmosphere containing
5% CO2. Each mouse was inoculated subcutaneously in
the right flank with 2 × 107 A431 or A549 cells.
Experimental design
Sixteen mice were implanted with A431 cells and
ten with A549 cells. After the tumors had grown to an
approximate size of 150 mm3, each group was randomly
divided into two subgroups. Ten A431-implanted and
five A549-implanted mice were intragastrically adminis-
tered 100 mg/kg/day gefitinib, whereas six and five mice,
respectively, were administered sterile water, as control.
18 F-FDG microPET-CT was performed the day before
gefitinib administration (day 0) and on days 2, 7, and 14.
The mice were subsequently sacrificed, and the tumor
tissues rapidly resected. Tumors that had decreased in
size ≥20% on day 14 were regarded as sensitive group;
those that remained unchanged in size or had increased
slowly, to a size smaller than that in the control group,
were regarded as stable; and those that had increased to
a size not significantly different from that of the control
group were regarded as resistant.
18 F-FDG microPET-CT imaging
18 F-FDG was kindly provided by the PET-CT Center,
Cancer Hospital, Chinese Academy of Medical Sciences,
Peking Union Medical College. The Siemens Inveon
combined microPET-CT scanner (Siemens Preclinical
Solution USA, Inc., Knoxville, TN, USA) was provided
by the Institute of Laboratory Animal Science, Chinese
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Center, Peking Union Medical College. MicroCT scans
were performed with an X-ray tube voltage of 80 kV, a
current of 500 μA, an exposure time of 130 ms, and 120
rotation steps. The mice were anesthetized with isoflur-
ane (2% in 100% oxygen) and, 10 min later, were injected
intravenously with 290 ~ 320 μCi of 18 F-FDG in 200 μL
saline. Imaging was started 60 min later. During scan-
ning, each mouse was placed prone on the examination
bed, and isoflurane (2% in 100% oxygen), with anesthesia
maintained and lasting for 20 min. All microPET data
were reconstructed with the filtered back-projection re-
construction algorithm.
Quantitative image analysis
Images were analyzed with the Inveon Research Work-
place (Siemens, Erlangen, Germany). Regions of interest
(ROIs) were drawn manually following qualitative as-
sessment of the entire tumor. The maximal percentage
of injected dose per gram of tissue (%ID/gmax) was deter-
mined using ROIs drawn around areas of increased
tracer accumulation on serial microPET images [15].
Tumor volume was determined by summation of voxels
within the tomographic planes on serial CT images. The
tumor volume response to therapy was expressed as ΔVo-
lumeday n = [(Volumeday n −Volumeday 0)/Volumeday 0] ×
100%, and the %ID/gmax response as Δ%ID/gmax day n = [(%
ID/gmax day n −%ID/gmax day 0)/%ID/gmax day 0] × 100%, as
described [15]. All images were traced by an investigator
blinded to treatment assignment.
Histopathologic examination
Following tumor resection, each was cut open across its
maximum dimension, fixed in 10% formalin, embedded
in paraffin, sectioned at 4 mm thick with a microtome
(RM2255, Leica Biosystems, Nussloch, Germany), and
stained with hematoxylin and eosin. Pictures taken at
high magnification (×200) were analyzed using Image-
Pro Plus 6.0 professional image analysis software [16].
On each histopathologic slide, five high-power fields
were randomly chosen for counting (one each in the
upper left, upper right, lower left, lower right, and mid-
dle). Necrotic areas were measured, and the necrotic
fraction of each field was expressed as a percentage.
Statistical analysis
Results were presented as mean ± SD. Tumor responses
in each group were evaluated by ANOVA. Statistical
analyses were performed to correlate the percent necro-
sis per specimen with the change in %ID/gmax day 14. The
areas under the receiver operating characteristic (ROC)
curves (area under the curve, AUC) of %ID/gmax or Δ%
ID/gmax on days 2, 7, and 14 were calculated by using a
nonparametric method to assess whether an AUC of 0.5for %ID/gmax or Δ%ID/gmax could discriminate between
tumors sensitive and stable to gefitinib and to determine
the possible AUC cutoff points for %ID/gmax and Δ%ID/
gmax. P values less than 0.05 were considered statistically
significant. Data from A431 and A549 tumors were ana-
lyzed independently.
Results
Changes in tumor volume on microCT
Before gefitinib treatment, there were no significant dif-
ferences in the volumes of A431 (n = 16) and A549 tu-
mors (n = 10) [(201.54 ± 40.38 mm3) vs. (213.40 ±
69.23 mm3), P = 0.092]. Measurement of A431 tumor
volume after 14 days of gefitinib treatment showed that
six of these tumors were sensitive, four were stable, and
none was resistant to gefitinib treatment. Before treat-
ment, the mean volume of tumors found to be sensitive
(215.78 ± 33.57 mm3) and stable (193.45 ± 42.81 mm3) to
gefitinib was similar to that in untreated mice (192.70 ±
42.71 mm3). On day 2, the changes in mean tumor vol-
ume in these three groups were −12.13% ± 6.79%, 3.22%
± 6.79%, and 70.28% ± 30.81%, respectively, with no sig-
nificant difference between the sensitive and stable
groups (P = 0.169). On day 7, the changes from baseline
in mean tumor volumes were −34.01% ± 7.17%, 12.02%
± 14.92%, and 229.65% ± 50.85%, respectively, with
gefitinib-sensitive tumors being significantly smaller than
gefitinib-stable (P = 0.034) and untreated (P = 0.000) tu-
mors. On day 14, mean tumor volumes in these three
groups were 143.65 ± 21.73, 264.90 ± 73.35, and 852.48 ±
99.42 mm3, respectively, corresponding to mean changes
from baseline of −32.97% ± 7.91% (P = 0.047), 35.91% ±
18.51% (P = 0.000), and 357.21% ± 83.09% (P = 0.000), re-
spectively (Figure 1).
Examination of tumor volume in the mice implanted
with A549 cells and treated for 14 days showed that
none was sensitive or stable to gefitinib, whereas five
were resistant. Before treatment, the mean volumes of
A549 tumors were treated, and untreated tumors were
240.10 ± 40.01 and 186.70 ± 86.02 mm3 (P = 0.125), re-
spectively. The mean changes in tumor volume were
7.92% ± 11.64% and 11.47% ± 6.16% (P = 0.739), respect-
ively, on day 2; 25.91% ± 18.47% and 50.03% ± 36.22% on
day 7 (P = 0.235), respectively; and 47.70% ± 28.19% and
91.93% ± 56.55% (P = 0.174), respectively, on day 14.
A549 tumor volumes before and after treatment did not
differ significantly between gefitinib-treated and un-
treated mice groups at these time points (P > 0.05).
Changes in 18 F-FDG uptake on microPET
18 F-FDG uptake by A431 and A549 tumors prior to
treatment differed significantly (P = 0.001). Before treat-
ment, 18 F-FDG uptake by A431 tumors sensitive and
stable to gefitinib and by untreated tumors was similar
Figure 1 Changes in A431 tumor volume during treatment
with gefitinib. No significant differences were seen among the
groups on days 0 and 2 (P > 0.05). Significant differences among the
groups were observed on days 7 and 14 (P < 0.05).
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gmax decreased markedly in the gefitinib-sensitive group
(−30.92% ± 6.66%) and slightly in the gefitinib-stable
group (−5.68% ± 6.95%), but increased in the untreated
group (7.72% ± 3.85%) (P = 0.000 for each pairwise com-
parison). At all time points, there were significant differ-
ences in changes of tumor 18 F-FDG uptake. %ID/gmax
gradually increased in the untreated group, but de-
creased slightly after day 7 (Figure 3).
In contrast, 18 F-FDG uptake by A549 tumors did not
differ significantly in gefitinib-treated and untreated
mice (Figure 4). The %ID/gmax of A549 tumors in both
groups gradually increased over time, but decreased
slightly after day 7.
ROC curve analysis of FDG uptake by A431 tumors
ROC curve analysis was performed to assess whether %
ID/gmax or Δ%ID/gmax could discriminate between tumorsFigure 2 Changes in A431 tumor 18 F-FDG uptake during
treatment with gefitinib. No significant differences were seen
among the groups on day 0 (P > 0.05), although significant
differences were observed on days 2, 7, and 14.sensitive and stable to gefitinib and to explore the possible
threshold of %ID/gmax or Δ%ID/gmax that could accurately
predict response to gefitinib. The Δ%ID/gmax of these tu-
mors on days 2, 7, and 14 monitored treatment sensitivity
(AUC = 1.000, P = 0.011 each). However, %ID/gmax of
A431 tumors on days 2, 7, and 14 failed to differentiate be-
tween tumors sensitive and stable to gefitinib, with AUCs
of 0.792 (P = 0.136), 0.667 (P = 0.394), and 0.813 (P =
0.110), respectively. Threshold with the maximum Youden
index was used to calculate the sensitivity and specificity
of this parameter. The cutoff point of Δ%ID/gmax on day 2
was −16.0%, which had a 100% sensitivity and a 100% spe-
cificity for predicting sensitivity to gefitinib.
Semiquantitative analysis of histopathologic findings
On day 14, necrosis was obvious in all three groups of
A431 tumors, but necrotic areas were significantly lar-
ger in gefitinib-sensitive (90.57% ± 4.77%) than in
gefitinib-stable (79.90% ± 7.76%, P = 0.045) and untreated
(69.04% ± 7.80%, P = 0.000) tumors, as well as being sig-
nificantly larger in gefitinib-stable than in untreated tu-
mors (P = 0.042). In A549 tumors, the mean percent
necrosis on day 14 was similar in gefitinib-treated (66.95%
± 9.06%) and untreated (65.66% ± 9.24%) mice (P = 0.795).
Discussion
Small-molecule EGFR-TKI drugs have shown survival
benefits in certain patient subpopulations, including fe-
male gender, Asian ethnicity, non-smokers, adenocarcin-
oma, and specific mutations of the EGFR kinase domain
[3,5]. Conversely, these characteristics are absent from a
sizable subgroup of patients with tumors that do re-
spond to EGFR-TKIs. Thus, it is very difficult to predict
the outcomes of EGFR-TKI therapy based on patient
and tumor factors alone. 18 F-FDG PET may therefore
be an alternative method of predicting tumor response,
by measuring early changes in tumor uptake of 18 F-FDG.
This study showed that 18 F-FDG uptake by A431 xeno-
grafts decreased after only 2 days of treatment, consisting
of two oral doses of gefitinib. After 14 days of treatment,
the tumor volume of A431 xenografts decreased or
remained stable, while the mean percent tumor necrosis
differed significantly in gefitinib-treated and untreated
mice. Conversely, treatment of gefitinib-resistant A549 xe-
nografts resulted in an increase, not a decrease, in FDG
uptake during the course of therapy, with the mean vol-
ume and percent necrosis of tumors not differing signifi-
cantly in gefitinib-treated and untreated mice after
14 days. These findings suggest that decreased 18 F-FDG
uptake, starting after only 2 days of treatment, could re-
flect the volumetric and pathological changes observed
after 14 days.
SUV of 18 F-FDG has been used to differentiate be-
tween benign and malignant tumors and to monitor
Figure 3 MicroPET-CT imaging of A431 tumors before and after gefitinib treatment. (A) Gefitinib-sensitive tumors on day 2, 7, and 14.
(B) Gefitinib-stable tumors on day 2, 7, and 14. (C) Tumors in the control group on day 2, 7, and 14. White arrow indicates tumor.
Figure 4 MicroPET-CT imaging of A549 tumors before and after gefitinib treatment. Tumors in the treated (A) and control (B) groups on
day 2, 7, and 14. White arrow indicates tumor.
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reported to correlate with SUV are tumor histological
type, degree of differentiation, and tumor cell prolifera-
tion [18]. We also found that 18 F-FDG uptake by A431-
and A549-generated tumor differed significantly before
therapy. The volume of A431 tumor xenografts de-
creased or remained stable after 14 days of treatment,
whereas the volume of A549 tumors was similar in
gefitinib-treated and untreated mice. Both cell lines ex-
press wild-type EGFR, but this gene is amplified and
overexpressed in A431 cells, explaining their higher drug
sensitivity, whereas A549 cells have a Ras mutation that
is responsible for resistance.
Changes in tumor 18 F-FDG uptake from baseline have
been used to evaluate responses to treatment and predict
survival. For example, chemotherapy-induced changes in
glucose metabolism were found to be highly predictive
of survival in 50 patients with advanced rectal carcinoma
[19]. A study of 50 consecutive patients with locally ad-
vanced NSCLC who received induction chemotherapy
or chemoradiotherapy found that a decrease in SUV
from baseline to after three chemotherapy cycles was
correlated with histopathologic response and prognosis
[20]. Change in tumor 18 F-FDG uptake was a better pre-
dictor of prognosis than in tumor 18 F-FDG uptake itself,
since the latter is a momentary measurement. Since 18 F-
FDG uptake varies widely among patients, a comparison
with pre-treatment 18 F-FDG uptake could be used to
monitor changes in tumor metabolic activity. Similarly,
we found that A431 tumor 18 F-FDG uptake on days 2,
7, and 14 did not differ significantly in tumors sensitive
and stable to treatment and in untreated tumors,
whereas changes in tumor 18 F-FDG uptake differed sig-
nificantly in all three groups. These results showed that
changes in 18 F-FDG uptake reflected the dynamic re-
sponse of tumors to treatment and provided better and
more personalized information than a single determin-
ation of 18 F-FDG uptake. Changes in 18 F-FDG uptake
may be more reliable in assessing response to treatment,
guiding individual treatments, and evaluating therapeutic
efficacy and patient prognosis.
A study of changes in tumor 18 F-FDG uptake from be-
fore to after 7 days of preoperative neoadjuvant EGFR-TKI
treatment in 23 patients with NSCLC found that a ≥ −25%
change in 18 F-FDG uptake 7 days after treatment could
predict tumor remission (histopathological response) and
increased tumor necrosis [14]. Our histopathologic analysis
showed that the necrotic areas of tumors sensitive and
stable to gefitinib differed significantly from each other
and from necrotic areas in untreated tumors. After
2 days of gefitinib administration, sensitive tumors
showed a 30% decrease in metabolic activity, whereas
stable tumors showed <10% decrease, indicating that
changes in 18 F-FDG can predict pathological responseand the effectiveness of gefitinib targeted therapy. Early
changes in tumor 18 F-FDG uptake have been closely re-
lated with sensitivity to therapy and prognosis [21-23].
However, specific criteria to determine early 18 F-FDG
PET response have not yet been defined, because of the
involvement of many factors, such as tumor type, size,
cell proliferation and diversity, time of evaluation, and
inter-individual differences. A study of changes in 18 F-
FDG uptake from before to after 14 days of neoadjuvant
chemotherapy in patients with gastric cancer proposed
a 35% reduction in 18 F-FDG uptake as a standard of
treatment response and good prognosis [24]. The re-
sults of the PERCIST study recommended that a ≥30%
decrease in tumor 18 F-FDG uptake after 4 weeks of
treatment be a criterion for solid tumor remission [25].
Similarly, a 18 F-FDG PET evaluation of five NSCLC pa-
tients before and 2 days after the initiation of gefitinib
therapy found that tumor uptake of 18 F-FDG was re-
duced 26% to 43% in patients who benefited from treat-
ment [26]. An investigation of changes in 18 F-FDG
uptake over 2 days in 20 patients with lung adenocar-
cinoma receiving gefitinib therapy found that a 25% cut-
off of SUV reduction was not significantly associated
with PFS (P = 0.095) [26], whereas a 20% cutoff showed a
significant relationship between metabolic response and
longer PFS (P < 0.0001). The threshold of 18 F-FDG uptake
changes determined by ROC curve analysis in the current
study was a 16.0% reduction on day 2. However, mean Δ%
ID/gmax on day 2 was 7.72% ± 3.85% in untreated mice,
similar to the coefficient of variation of 18 F-FDG uptake
threshold and likely due to high experimental variability.
We observed that untreated tumors were several times
larger on day 14 than before treatment, while tumor up-
take had decreased after 7 days. Rapidly growing trans-
planted tumors may not be provided with sufficient blood
supply by the host. However, metabolic uptake is associ-
ated with tumor blood supply, not tumor volume [27],
which may explain the reduction in %ID/gmax on day 14.
Although these results indicate that 18 F-FDG PET can
be used to monitor tumor response to EGFR-TKIs, several
limitations should be noted. First, both the A431 and A549
cell lines express the wild-type EGFR. Additional studies
are needed to assess mice bearing human tumors express-
ing EGFR with kinase domain mutations. Animal experi-
ments provided a rigorous test of our hypotheses, but the
clinical complexity of inter-individual differences and the
cutoff value for 18 F-FDG uptake indicating clinical benefits
from treatment required determination. However, thresh-
old values are highly dependent on the number of subcuta-
neously injected tumor cells. For example, tumor cells
expressing mutated EGFR may have different thresholds of
changes in 18 F-FDG uptake at early time points. In
addition, human cancers are more complex and heteroge-
neous than mouse tumor xenografts. Other clinically
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tumor 18 F-FDG uptake during gefitinib treatment. There-
fore, changes in 18 F-FDG uptake may not be as dramatic
in patients as in mouse tumor xenografts.
Conclusions
Our findings suggest that response to gefitinib treat-
ment, as assessed by 18 F-FDG PET, could help identify
treatment sensitive tumors by their significant decrease
in glucose metabolism. 18 F-FDG PET-CT is a sensitive
and noninvasive method that may enable the selection
of patients likely to benefit from gefitinib treatment.
Confirming that reduced 18 F-FDG uptake could predict
tumor response to gefitinib at early time points allowing
the more sensitive detection of gefitinib-sensitive tumors
and reduce drug side effects in clinical trials. Further
studies, however, are needed to determine the optimal
response criteria for various target therapies.
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